Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

Advertisements

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

Volume 64, Issue 5, Pages (November 2013)

Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.

Volume 155, Issue 3, Pages (March 1996)

Bladder Cancer and Prostatic Cancer

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

New Tracers for Prostate Cancer Imaging

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Nat. Rev. Urol. doi: /nrurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Volume 199, Issue 1, Pages (January 2018)

Jaden D. Evans, MD, Krishan R

Advances in the Treatment of Metastatic Prostate Cancer

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Volume 64, Issue 5, Pages (November 2013)

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key elements of the proposed modified Delphi study

Updates in Detection and Management of BCRPC

Volume 65, Issue 4, Pages (April 2014)

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 13 Proposed management of bladder cancer with variant histology

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies Steven P. Rowe, Kenneth J.

Figure 3 Algorithm for the determination of the clinical

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Nat. Rev. Urol. doi: /nrurol

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 6 Image sequence demonstrating coronal cuts on MRI

Nat. Rev. Urol. doi: /nrurol

Figure 4 New PET radiotracers in lymphoma

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Variations between planned and delivered doses of radiation

Figure 2 The evolution of brachytherapy for prostate cancer

European Urology Oncology

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Urol. doi: /nrurol

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Figure 3 Target volume definitions

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes Following irreversible electroporation (IRE)

Figure 4 Algorithm for when to determine PTEN

A and B, CT images on a patient status post total thyroidectomy for thyroid cancer show a small enhancing lesion near the right tracheoesophageal groove.

History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Patient 10. Patient 10. A 67-year-old man after radiation therapy at an outside hospital for base-of-tongue cancer. A and B, Axial contrast-enhanced CT.

Serial CT scan images from patient with a partial response.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.175 Figure 1 Recurrent prostate cancer detected with PSMA-targeted 18F-DCFPyL PET–CT Figure 1 | Recurrent prostate cancer detected with PSMA-targeted 18F-DCFPyL PET–CT. The patient presented approximately 5 years after radical prostatectomy with a serum PSA of 0.43 ng/ml and without evidence of disease on bone scan or contrast-enhanced CT. The (a) maximal intensity projection and (b) fused PET–CT axial images demonstrate recurrent disease in the transverse process of T7 (red arrows). The patient was successfully treated with stereotactic body radiation to the lesion. Tosoian, J. J. et al. (2016) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Nat. Rev. Urol. doi:10.1038/nrurol.2016.175